It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Pancreatic cancer (PC) is one of the leading causes of mortality rate globally and is usually associated with obstructive jaundice (OJ). Up to date, there is no clear consensus on whether biliary decompression should be performed prior to surgery and how high levels of serum bile affects the outcome of PC. Therefore, our study aims were to characterise the effect of bile acids (BAs) on carcinogenic processes using pancreatic ductal adenocarcinoma (PDAC) cell lines and to investigate the underlying mechanisms. Liquid chromatography-mass spectrometry was used to determine the serum concentrations of BAs. The effects of BAs on tumour progression were investigated using different assays. Mucin expressions were studied in normal and PDAC cell lines and in human samples at gene and protein levels and results were validated with gene silencing. The levels of BAs were significantly higher in the PDAC + OJ group compared to the healthy control. Treating PDAC cells with different BAs or with human serum obtained from PDAC + OJ patients enhanced the rate of proliferation, migration, adhesion, colony forming, and the expression of MUC4. In PDAC + OJ patients, MUC4 expression was higher and the 4-year survival rate was lower compare to PDAC patients. Silencing of MUC4 decreased BAs-induced carcinogenic processes in PDAC cells. Our results show that BAs promote carcinogenic process in PDAC cells, in which the increased expression of MUC4 plays an important role. Based on these results, we assume that in PC patients, where the disease is associated with OJ, the early treatment of biliary obstruction improves life expectancy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Szeged, Department of Pharmacology and Pharmacotherapy, Szeged, Hungary (GRID:grid.9008.1) (ISNI:0000 0001 1016 9625)
2 University of Szeged, Regenerative Medicine and Cellular Pharmacology Research Laboratory, Department of Dermatology and Allergology, Szeged, Hungary (GRID:grid.9008.1) (ISNI:0000 0001 1016 9625); University of Szeged, HCEMM SZTE Skin Research Group, Szeged, Hungary (GRID:grid.9008.1) (ISNI:0000 0001 1016 9625)
3 University of Szeged, Department of Microbiology, Szeged, Hungary (GRID:grid.9008.1) (ISNI:0000 0001 1016 9625)
4 University of Szeged, Department of Pathology, Szeged, Hungary (GRID:grid.9008.1) (ISNI:0000 0001 1016 9625)
5 University of Szeged, First Department of Medicine, Szeged, Hungary (GRID:grid.9008.1) (ISNI:0000 0001 1016 9625)
6 University of Szeged, First Department of Medicine, Szeged, Hungary (GRID:grid.9008.1) (ISNI:0000 0001 1016 9625); University of Pécs, Institute for Translational Medicine, Medical School, Szentágothai Research Centre, Pécs, Hungary (GRID:grid.9679.1) (ISNI:0000 0001 0663 9479); University of Pécs, Division of Gastroenterology, First Department of Medicine, Medical School, Pécs, Hungary (GRID:grid.9679.1) (ISNI:0000 0001 0663 9479)